Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strattera in Adults With ADHD NOS
NCT00181766Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2003
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Massachusetts General Hospital. Primary endpoints: ADHD-Clinical Global Impression at 6 weeks and Adult ADHD Investigator Symptom Rating Scale at 6 weeks. Started Dec 2003; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00181766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00181766.